Thomas Holst‐Hansen
Impact in
- Pharmacology top 5%
- Pharmacology and Obesity Treatment
-
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
Papers in
-
- Pharmacology and Obesity Treatment 7
- Cannabis and Cannabinoid Research 1
-
- Diabetes Treatment and Management 4
- Co-authors
- William Timothy Garvey (3 shared papers)Peter Nørkjær Laursen (3 shared papers)Ruben Duque do Vale (1 shared paper)Filip Krag Knop (3 shared papers)Vanita R. Aroda (1 shared paper)Domenica Rubino (1 shared paper)Julio Rosenstock (1 shared paper)Ala Trusina (2 shared papers)
- Journals
- Diabetes Obesity and Metabolism (5 papers)The Lancet (1 paper)Canadian Journal of Cardiology (1 paper)Science Advances (1 paper)Obesity (1 paper)
- Partner nations
- DenmarkUnited StatesCanada
In The Last Decade
Thomas Holst‐Hansen
12 papers receiving 371 citations
Thomas Holst‐Hansen's Hit Papers
Peers
Comparison fields: 5 of 50
- Pharmacology 183
- Endocrinology, Diabetes and Metabolism 123
- Pharmacy 8
- Endocrine and Autonomic Systems 7
- Pharmaceutical Science 6
Countries citing papers authored by Thomas Holst‐Hansen
This map shows the geographic impact of Thomas Holst‐Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Holst‐Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Holst‐Hansen more than expected).
Fields of papers citing papers by Thomas Holst‐Hansen
This network shows the impact of papers produced by Thomas Holst‐Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Holst‐Hansen. The network helps show where Thomas Holst‐Hansen may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Holst‐Hansen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 309 |
| 2 | 2022 | 27 | |
| 3 | 2023 | 14 | |
| 4 | 2024 | 8 | |
| 5 | 2022 | 5 | |
| 6 | 2023 | 5 | |
| 7 | 2025 | 5 | |
| 8 | 2024 | 3 | |
| 9 | 2024 | 2 | |
| 10 | 2022 | 1 | |
| 11 | 2023 | 1 | |
| 12 | 2024 | 1 | |
| 13 | 2026 | 0 | |
| 14 | 2026 | 0 |
About Thomas Holst‐Hansen
Thomas Holst‐Hansen is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism, Economics and Econometrics, Cancer Research and Public Health, Environmental and Occupational Health, having authored 14 papers that have together received 381 indexed citations. Recurring topics across this work include Pharmacology and Obesity Treatment (7 papers), Diabetes Treatment and Management (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Pancreatic function and diabetes (1 paper), Obesity, Physical Activity, Diet (1 paper), Cannabis and Cannabinoid Research (1 paper) and NF-κB Signaling Pathways (1 paper). The work is most often cited by research in Pharmacology (183 citations), Endocrinology, Diabetes and Metabolism (123 citations), Pharmacy (8 citations), Endocrine and Autonomic Systems (7 citations) and Pharmaceutical Science (6 citations). Thomas Holst‐Hansen has collaborated with scholars based in Denmark, United States and Canada. Frequent co-authors include William Timothy Garvey, Peter Nørkjær Laursen, Ruben Duque do Vale, Filip Krag Knop, Vanita R. Aroda, Domenica Rubino, Julio Rosenstock, Ala Trusina, Sara Saheb Kashaf and Minjun Son. Their work appears in journals such as Diabetes Obesity and Metabolism, The Lancet, Canadian Journal of Cardiology, Science Advances and Obesity.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.